9DC Stock Chart & Stats
€7.75
-€0.05(-0.64%)
At close: 4:00 PM EDT
€7.75
-€0.05(-0.64%)
Day’s Range― - ―
52-Week Range€6.05 - €9.00
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€2.03B
Enterprise Value€571.20K
Total Cash (Recent Filing)€68.81B
Total Debt (Recent Filing)€304.25B
Price to Earnings (P/E)37.4
Beta0.66
Next Earnings
Oct 29, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)38.74
Shares Outstanding256,142,670
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)0.91
Price to Sales (P/S)0.56
P/FCF Ratio128.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.11Price Target Upside4.69% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.69
Revenue Forecast (FY)€3.35B
Bulls Say, Bears Say
Bulls Say
Diversified Product & End-market ExposureDaicel's diversified mix of specialty chemicals, engineered materials and safety-related automotive components provides durable demand across automotive, electronics and industrial end markets. This multi-market exposure reduces single-sector cyclicality and supports recurring B2B contracts and long product lifecycles, aiding revenue resilience over time.
Steady Multi-year Revenue GrowthConsistent multi-year revenue growth signals underlying market demand and steady customer retention for Daicel's products. A constructive top-line trajectory supports better capacity utilization and provides a platform to invest in higher-value specialty offerings, which can help stabilize revenues while management addresses margin and cash-flow variability.
Improving Leverage And Equity GrowthReported leverage falling to roughly 0.8x of equity and rising equity levels enhance financial resilience. Reduced leverage relative to prior periods lowers refinancing strain and interest burden risk, improving the company's ability to fund strategic investments, manage working capital swings, and sustain operations through medium-term profit cycles.
Bears Say
Profitability DeteriorationA sharp decline in net income and compressed operating profit point to meaningful margin pressure. Sustained profitability weakness undermines internal funding for R&D, capex and dividends, increases sensitivity to raw-material and energy cost swings, and reduces the firm's ability to build financial buffers against future downturns.
Volatile And Weak Free Cash FlowVolatile free cash flow—including negative years—indicates inconsistent cash conversion and constrains financial flexibility. This variability limits the company's ability to consistently fund strategic projects, sustain dividends or reduce debt, and increases reliance on external financing during weaker operating periods.
Sizable Absolute Debt And Borrowing RelianceDespite leverage improvement, total debt remains sizable and the business still leans on borrowing. Meaningful absolute debt raises interest and refinancing risk, which can amplify earnings volatility and constrain capital allocation if profitability or cash flows deteriorate further, limiting long-term strategic flexibility.
Daicel News
9DC FAQ
What was Daicel’s price range in the past 12 months?
Daicel lowest stock price was €6.05 and its highest was €9.00 in the past 12 months.
What is Daicel’s market cap?
Daicel’s market cap is €2.03B.
When is Daicel’s upcoming earnings report date?
Daicel’s upcoming earnings report date is Oct 29, 2026 which is in 89 days.
How were Daicel’s earnings last quarter?
Daicel released its earnings results on Jul 30, 2026. The company reported €0.202 earnings per share for the quarter, beating the consensus estimate of €0.123 by €0.079.
Is Daicel overvalued?
According to Wall Street analysts Daicel’s price is currently Undervalued.
Does Daicel pay dividends?
Daicel does not currently pay dividends.
What is Daicel’s EPS estimate?
Daicel’s EPS estimate is 0.12.
How many shares outstanding does Daicel have?
Daicel has 256,142,670 shares outstanding.
What happened to Daicel’s price movement after its last earnings report?
Daicel reported an EPS of €0.202 in its last earnings report, beating expectations of €0.123. Following the earnings report the stock price went up 3.947%.
Which hedge fund is a major shareholder of Daicel?
Currently, no hedge funds are holding shares in DE:9DC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daicel
Daicel Corporation, a Japanese enterprise founded in Osaka in 1919, conducts its business operations across Japan, Asia, North America, and Europe. The company is a key producer and distributor of a broad array of products, including cellulosic derivatives, organic chemicals, diverse plastics, and pyrotechnic devices. Its extensive activities are organized into distinct segments: Medical/Healthcare, Smart, Safety, Materials, Engineering Plastics, and other specialized areas. In the Medical/Healthcare sector, Daicel supplies various cosmetic components such as 1,3-Butylene glycol, polyglycerin, and thickeners, in addition to natural health food ingredients and dietary supplements. For the pharmaceutical industry, it provides specialized chiral and achiral columns, a variety of chiral and bio reagents, and DNA/RNA-based probes, supported by comprehensive analytical, purification, synthesis, formulation, and specialized analytical tool services. The "Smart" segment focuses on advanced materials for the electronics industry, offering triacetylcellulose and films for display technologies, solvents for electronic applications, polymers for resist processes, and cleaning agents for semiconductors. Moreover, Daicel contributes to visualization technologies with its optical components, lens units, silver nanoparticle inks, and organic semiconductor devices. Within the Safety domain, the company manufactures inflators for vehicle airbags and pyro-fuses, alongside safety mechanisms for non-automotive products. Daicel is also a significant supplier of foundational chemicals and raw materials, including acetic acid and its derivatives, cellulose acetate, and acetate tow for resins, inks, and paint solvents. It further develops specialty chemicals such as cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines, which are vital for electrical materials and coatings. For the Engineering Plastics segment, Daicel delivers a wide selection of plastic solutions, encompassing engineering plastics, plastic compound products, functional sheets, molded trays, and packaging films. Beyond these core offerings, the company also produces water treatment systems and diffusers tailored for diverse industrial requirements. Daicel's comprehensive portfolio plays a crucial role in various sectors, including transportation, electronics, medical care, personal care, daily life, and environmental and energy applications. The company, which was initially named Daicel Chemical Industries, Ltd., officially adopted its current name, Daicel Corporation, in October 2011.
9DC Stock 12 Month Forecast
Average Price Target
€8.11
▲(4.69% Upside)
Technical Analysis
Kaneka
―
Mitsubishi Gas Chemical Company
―
UBE Industries
―
Zeon
―
Sumitomo Bakelite Co., Ltd.
―










